15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Viking Therapeutics Inc, 7 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $75.00 to $125.00, a moderate spread. The average target of $100.00 sits 187% above the current $34.88. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.10 next quarter toward $-4.57 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Moderate Buy
Strong Buy00%
Buy7100%
Hold00%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Viking Therapeutics Inc.
As of Jul, 7 of 7 firms rate VKTX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
VKTX EPS & revenue forecast
EPS · NEXT QUARTER
$-1.10
Range $-1.45 – $-0.75 · 16 analysts · +36% YoY
Next period, 16 analysts expect Viking Therapeutics Inc to earn $-1.10 a share (range $-1.45 – $-0.75), versus $-0.81 a year earlier. Full-year consensus is $-4.72, growing to $-4.57 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 16 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Viking Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VKTX.
#1
Mayank Mamtani
B. Riley Securities · Rank #9
Buy
$96.00+175.2% to target
Overall win rate
53%
+ Follow
#2
Joseph Pantginis
HC Wainwright & Co. · Rank #266
Buy
$102.00+192.4% to target
Overall win rate
32%
+ Follow
#3
Jay Olson
Oppenheimer · Rank #302
Buy
$100.00+186.7% to target
Overall win rate
32%
+ Follow
#4
MU
Michael Ulz
Morgan Stanley
Buy
$95.00+172.4% to target
Coverage
—
+ Follow
#5
Ryan Deschner
Raymond James
Buy
No targeton VKTX
Coverage
—
+ Follow
VKTX stock forecast FAQ
What is VKTX's average 12-month price target?+
The 7 analysts with a live target average $100.00 for Viking Therapeutics Inc over the next 12 months, ranging from a $125.00 high to a $75.00 low.
Is VKTX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 7 analyst ratings, 7 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for VKTX?+
The Street-high target is $125.00 (BTIG), and the Street-low is $75.00 (JP Morgan). The average of all 7 active targets is $100.00.
How many Wall Street analysts cover VKTX?+
7 analysts have an active rating on Viking Therapeutics Inc, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering VKTX?+
Among analysts who currently cover VKTX, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #9). Their current call is Buy with a $96.00 target.
What is Viking Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.10 per share (range $-1.45 – $-0.75) across 16 analysts. Full-year EPS is projected at $-4.72, rising to $-4.57 the following year.
How much revenue is Viking Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading VKTX lately?+
As of Jul, 7 of 7 firms rate VKTX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VKTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
